Hepatitis B virus (HBV) causes chronic hepatitis in hundreds of millions of people worldwide, which can eventually lead to hepatocellular carcinoma (HCC). The molecular mechanisms underlying HBV persistence are not well understood. TRAIL, the TNF-related apoptosis-inducing ligand, has recently been implicated in hepatocyte death during HBV infection. We report here that the HBV core protein (HBc) is a potent inhibitor of TRAIL-induced apoptosis. Overexpressing HBc significantly decreased TRAIL-induced apoptosis of human hepatoma cells, whereas knocking-down HBc expression in hepatoma cells transfected with HBV genome enhanced it. When present in the same cell, HBc blocked the pro-apoptotic effect of the HBV X protein (HBx). The resistance of HBc-expressing cells to TRAIL-induced apoptosis was associated with a significant reduction in death receptor 5 (DR5) expression. Upon transfection, HBc significantly repressed the promoter activity of the human DR5 gene. Importantly, HBc gene transfer inhibited hepatocyte death in a mouse model of HBV-induced hepatitis; and in patients with chronic hepatitis, DR5 expression in the liver was significantly reduced. These results indicate that HBc may prevent hepatocytes from TRAIL-induced apoptosis by blocking DR5 expression, which in turn contributes to the development of chronic hepatitis and HCC. They also call into question the potential side effects of HBc-based vaccines. Hepatitis B virus (HBV) infection remains to be a major health problem worldwide despite the availability of an effective vaccine. More than 350 million people are chronically infected with HBV who are at a high risk of developing hepatitis, cirrhosis and hepatocellular carcinoma. 1 To date, the molecular mechanisms of chronic HBV infection have not been elucidated in detail. Recent studies suggest that resistance of HBV-infected hepatocytes to apoptosis may contribute to the development of chronic hepatitis. 2 Apoptosis of hepatocytes during HBV infection is mediated by several molecular pathways, which involve at least three members of the TNF superfamily, that is, TNF, Fas ligand (FasL) and TRAIL. Unlike TNF and FasL, TRAIL preferentially induces apoptosis of tumor cells and virus-infected cells but not normal cells. [3][4][5] Blocking the TRAIL pathway using soluble death receptor 5 (DR5) significantly ameliorates liver inflammation in a mouse model of hepatitis B. 6 Interestingly, two HBV proteins, HBV X (HBx) 5 and truncated middle hepatitis B surface protein (MHBs(t)), 7 were recently found to sensitize hepatocytes to TRAIL-induced apoptosis.The TRAIL apoptotic pathway is strictly controlled at both the receptor and intracellular signaling levels. Five receptors for TRAIL have been identified, including two death receptors (DR4 and DR5, also known as TRAIL-R1 and TRAIL-R2, respectively) and two decoy receptors (decoy receptor 1(DcR1, TRAIL-R3, and TRID) and decoy receptor 2 (DcR2, TRAIL-R4, and TRUNDD)). 4,8,9 In mice, only one membrane TRAIL receptor has been identified, which shares 79% sequenc...